ST. LOUIS, Aug. 21 /PRNewswire-FirstCall/ -- GenoMed , a Next Generation Disease Management company that uses genomics to solve diseases in as many species as possible, today announced that the third horse in its expanded trial for West Nile virus encephalitis recovered markedly within 24 hours after starting GenoMed’s treatment.
On Thursday afternoon last week, a horse owner in Fresno, California telephoned GenoMed to say that her horse was falling down. The horse had not been vaccinated for West Nile virus, and her veterinarian thought the horse had West Nile virus encephalitis.
Within 24 hours of the first dose of GenoMed’s treatment, the horse was chasing the other horses away from his food, which they had been eating while he was sick.
West Nile virus encephalitis affects horses more severely than people, and the odds of recovery are slimmer. Like people, horses usually recover from viral encephalitis over at least a week. Recovery within 24 hours, like all three of GenoMed’s horses, and most of GenoMed’s human patients, is extremely unusual.
Said Dr. Moskowitz, GenoMed’s CEO and Chief Medical Officer, “It’s always thrilling to watch patients get better. All the evidence for our treatment for the past four years, in humans, birds, and now horses, has been extremely positive.”
GenoMed’s treatment success rate for WNV encephalitis in people is currently 87% (20 of 23 patients improved rapidly). A small case series involving the company’s first 8 patients was published in a peer-reviewed medical journal in 2004.
About GenoMed
Anyone can download the West Nile virus protocol for humans and horses for free from GenoMed’s website, www.genomed.com, at any time. An email address is required for clinical follow-up.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company’s) treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
GenoMed
CONTACT: David W. Moskowitz MD of GenoMed, +1-314-983-9938,dwmoskowitz@genomed.com
Web site: http://www.genomed.com/
